AAA. V. Alekhin

A. V. Alekhin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


A. V. Alekhin has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Medical and pharmacological application of plants of the genus Epimedium L. (review)

    by Aleksey V. Alekhin, Mariya S. Smirnova, Vera Yu. Zhilkina, Anna I. Marakhova, А. В. Алехин, М. С. Смирнова, В. Ю. Жилкина, А. И. Марахова

    Introduction. Plants of the genus Epimedium L. (barrenwort) of the family Berberidaceae are widely used in traditional Chinese medicine, and five of their species are included in the Chinese Pharmacopoeia. The raw materials of barrenwort contain a complex of biologically active compounds, dominated by prenylated flavonoid glycosides, in particular icariin. In the Russian Federation, an icariin-based hygienic product in the form of toothpaste has been developed and patented. This actualizes the issue of distinguishing hygienic, cosmetic and pharmaceutical products, as well as the need for a critical assessment of the evidence base. The aim of the study is to systematize modern data on the chemical composition and pharmacological properties of plants of the genus Epimedium L. to substantiate the prospects of their application in medicine and dentistry. Text. The review presents the botanical characteristics and geographic range of the genus Epimedium L., describes its chemical composition in detail with an emphasis on icariin as the dominant component and the main marker for standardization. Summarized data on the species and geographical variability of the accumulation of flavonoids, as well as on other groups of biologically active substances (lignans, alkaloids, terpenoids) are presented. The key pharmacological effects were analyzed: effects on reproductive function (inhibition of phosphodiesterase type 5, increased testosterone levels, improved sperm quality), osteoprotective effect, immunomodulatory and anti-inflammatory activity. Special attention is paid to the application in dentistry: the ability of icariin to stimulate odontogenic differentiation of dental pulp stem cells, regeneration of the alveolar bone in periodontitis, and suppression of the growth of periodontal pathogens. The problems of the low oral bioavailability of icariin (about 12 %) and the prospects of alternative delivery routes, including a transbuccal route, which is implemented in a patented toothpaste composition, are considered. It is highlighted that, despite numerous preclinical data, systematic clinical studies of the efficacy and safety of icariin are limited. Conclusion. Representatives of the genus Epimedium L. are a promising source of biologically active compounds with a wide range of pharmacological activities, including reproductive, osteoprotective, immunomodulatory and regenerative. A key area of further research is the development of unified approaches to the standardization of raw materials and finished products, considering species specificity. Moreover, the study of the pharmacokinetics and bioavailability of icariin in alternative (transbuccal, transdermal) routes of administration is crucial for creating effective and safe standardized dosage forms.

  • Open Access

    Landscape of biotechnological innovations: analysis of the patent portfolio operating in the Russian Federation for the period from 2005 to 2024

    by T. N. Erivantseva, A. V. Alekhin

    The aim. To conduct a comparative analysis of long-term trends and structural features of patenting in the field of biotechnology at the national and regional levels. Materials and methods. The study is based on data from two patent offices: the Federal Service for Intellectual Property (Rospatent) and the Eurasian Patent Office (EAPO) for the period from 2005 to 2024. The methodology includes a quantitative analysis of patent applications with classification by applicant countries and industry areas of biotechnology. Results . It was found that the share of biotechnological patents is 4.68% in Rospatent and 8.33% in EAPO. The phenomenon of strategic duality was revealed: in the Russian Federation, Russian applicants dominate (61% of patents), while in the EAPO their share is only 9%, while non-residents form extensive patent portfolios there. The dynamics of patent activity demonstrates a clear correlation with external factors: an increase in the activity of non-residents in the EAPO after 2014 and a shift in industry priorities in the Russian Federation from medical to industrial biotechnology after 2019. At the same time, domestic patent activity in Rospatent has decreased by 16.5% the last five years. Conclusion . The results indicate a systemic imbalance: Russia pursues a predominantly internally oriented patent strategy, focusing on the domestic market, and is significantly inferior in the formation of legal positions in the Eurasian space. The predominance of foreign patents in the EAPO creates long-term risks for the competitiveness of Russian developments in the region. The data obtained can be useful in the development of state programs to improve Russia’s competitiveness in the framework of biotechnological areas in the global market.

  • Open Access

    CORRIGENDUM: Regulation in the sphere of circulation of extemporaneously compounded medicines under modern conditions of Russia [. Pharmacy & Pharmacology. 2024;12(5):324-337. DOI: 10.19163/10.19163/2307-9266-2024-12-5-324-337]

    by V. V. Ryazhenov, E. A. Maksimkina, V. S. Fisenko, A. V. Alekhin, V. V. Tarasov, M. G. Raisyan, E. R. Zakharochkina, K. A. Chizhov, R. Yu. Garankina

    Referred to by: Ryazhenov V.V., Maksimkina E.A., Fisenko V.S., Alekhin A.V., Tarasov V.V., Raisyan M.G., Zakharochkina E.R., Chizhov K.A., Garankina R.Yu. Regulation in the sphere of circulation of extemporaneously compounded medicines under modern conditions of Russia. Pharmacy & Pharmacology. 2024;12(5):324-337. https://doi.org/10.19163/2307-9266-2024-12-5-324-337 We hereby inform readers that in the final version of the article changes were made in Russian and English.In the published article " Regulation in the sphere of circulation of extemporaneously compounded medicines under modern conditions of Russia", the authors found an error: accidentally, due to a technical error on part and without any malicious intent, еhe regulatory document was incorrectly specified in table 1 (p.330):Resolution of the Government of the Russian Federation No. 546 “On Approval of the Regulations on Licensing of Pharmaceutical Activities” dated March 31, 2022.The authors regret that, due to an oversight, the cited regulatory document was incorrectly numbered (No. 546) in the originally published version of this article.Correct version:Resolution of the Government of the Russian Federation No. 547 “On Approval of the Regulations on Licensing of Pharmaceutical Activities” dated March 31, 2022. The error occurred due to the fault of the entire team of authors, but does not change the essence of the data presented in the article, does not violate their perception by readers or interpretation.The authors would like to apologize for any inconvenience. The authors declare no conflict of interest.The original article has been updated in online-version: https://www.pharmpharm.ru/jour/article/view/1664

  • Open Access

    Problems and Solutions of Pharmaceutical Packaging in Bulk

    by R. Yu. Garankina, V. V. Ryazhenov, E. A. Maksimkina, V. S. Fisenko, A. V. Alekhin, V. V. Tarasov, K. A. Chizhov, I. F. Samoshchenkova, N. Yu. Behorashvili, E. R. Zakharochkina

    To date, pharmaceutical activities in the manufacture of medicines in a pharmacy, intra-pharmacy packaging of registered medicines in Russia and the countries of the Eurasian Economic Union (EAEU), is one of the priorities of regulatory authorities in order to improve drug supply.The aim. To study the current state of legal regulation of the circulation of medicines “in bulk” and the possibility of their packaging in a pharmacy.Materials and methods. To solve the tasks set, the methodology of system analysis in the field of drug provision, content analysis of documents regulating the sphere of circulation of drugs was used. The regulatory framework of the study was the legislative and by-laws regulating the sphere of circulation of medicines of the Russian Federation and the common market of the EAEU. The search for regulatory legal acts was carried out in the Directory of the legal system “ConsultantPlus”. In the course of the research, a set of scientific methods was used such a systematic, logical, structural and comparative.Results. The article consider the issues of legal regulation of the circulation of medicines “in bulk” in the pharmaceutical market. The current state of the legislative and regulatory framework has been studied and the problems of legal regulation of packaging of medicicnes “in bulk” in pharmacies have been identified. The article also focuses on the general problem of compliance with modern packaging requirements for medicines compounded in pharmacy. The possibility of introducing a new concept of “Pharmacy packaging” into Federal Law No. 61-FZ dated April 12, 2010 “On the circulation of medicines” is considered. The approaches developed in world practice to the regulation of issues related to the packaging of drugs “in bulk” in pharmacy are considered. Based on the results of the study, the possibilities have been identified and ways to improve the mechanisms of state regulation have been proposed.Conclusion. Packaging of medicines “in bulk” will increase the effectiveness of individual drug therapy, optimize and reduce the cost of circulation of budget funds, pharmacies and citizens.


  • Open Access

    Regulation in the sphere of circulation of extemporaneously compounded medicines under modern conditions of Russia

    by V. V. Ryazhenov, E. A. Maksimkina, V. S. Fisenko, A. V. Alekhin, V. V. Tarasov, M. G. Raisyan, E. R. Zakharochkina, K. A. Chizhov, R. Yu. Garankina

    The aim of the work was to analyze the current regulatory legal framework governing the manufacture of drugs in pharmacies, and a comprehensive review of the current state of their manufacture; a disclosure of problems and search for the ways to improve the sphere of circulation of extemporaneously compounded medicines (ECMs).Materials and methods. The national legislation of the Russian Federation and the regulatory framework of the medicines common market of the Eurasian Economic Union in the field of an extemporaneous drugs circulation formed a regulatory base of the work. To collect and analyze the information data, the materials presented on the official websites of the Ministry of Health of Russia, the Ministry of Industry and Trade of Russia have been used. The results of the scientific publications for the previous 10 years (2014–2024) have also been analyzed.Results. The article deals with the current state issues of the drug products manufactured in pharmacies, in the sphere of circulation. The analysis of the legislative base on ECMs has been carried out, the problems of the normative legal regulation of the pharmacy drugs manufacturing have been identified. The introduction of new relevant concepts into Federal Law No. 61-FZ “On Circulation of Medicines” — “extemporaneous drug products”, “extemporaneous manufacturing”, “extemporaneous production” — has been proposed. The authors’ definition of the “pharmaceutical sovereignty” concept was given in the course of the study. Based on the results of the study, the possibilities and ways of improving the mechanisms of the state regulation of the drugs extemporaneous manufacturing in the current political and economic conditions have been identified.Conclusion. The operational management and systematization of the regulatory legal framework of the ECMs circulation sphere based on the regulatory science is the most important factor in increasing the affordable, effective, personalized pharmaceutical care. An important element of the mobilization model of the economy is strengthening of the state regulation, development of the domestic production capacities and technologies, including taking into account extemporaneous manufacturing of drugs and small-scale production.


  • Open Access

    The work of compounding pharmacies and the possible risks of violating the exclusive rights to original medicines

    by A. V. Alekhin, T. N. Erivantseva, V. O. Kalyatin, R. A. Ivanov, N. A. Alekhina

    The revival of production pharmacies in Russia began in 2022. To effectively use the capabilities of compounding pharmacies, it is necessary to take into account the importance of eliminating the risk of infringement of intellectual property rights.The aim. The study of the foreign practice of compounding pharmacies in terms of infringement of exclusive rights, as well as the position of foreign patent offices and the World Intellectual Property Organization (WIPO).Materials and methods. A key aspect of the research was the study of the foreign practice of violating the exclusive rights to original medicines. An information search was conducted for publications related to the activities of compounding pharmacies in the world, as well as issues related to the regulation of the relationship between their activities and legislation in the field of intellectual property.Results. The article analyzes foreign judicial practices and positions of patent offices, summarized by WIPO, on this issue. The results and discussion are based on the consideration of foreign court cases and legislative norms related to the production of patented drugs in compounding pharmacies. The examples of court cases that raise issues of violations of exclusive rights are given.Conclusion. In Russia, the possibility of one-time compounding of drugs using the invention in pharmacies according to doctors’ prescriptions is fixed at the legislative level. However, this permission only applies to a “specific recipe”. One possible way to reduce the severity of the problem may be to directly allow pharmacies to use contractors to fulfill a specific request. The concept of “one-time compounding” also requires disclosure, which may expand the capabilities of pharmacies. The results obtained can be used in the framework of legislative regulation of the compounding of medicines in a pharmacy.

  • Open Access

    Past, current and future of legal regulation of drugs compounding in the Russian Federation

    by D. D. Mamedov, D. S. Yurochkin, Z. M. Golant, V. S. Fisenko, A. V. Alekhin, I. A. Narkevich

    Today the activities of compounding pharmacies in terms of the drug compounding and in-pharmacy packaging of approval drugs is considered as a priority social task of the Russian Federation, due to the need to solve problems that are aimed at ensuring the strategic independence of the state from external and internal challenges, as well as threats, widespread introduction of personalized pharmacotherapy methods, opportunities in the field of optimizing the costs of the healthcare system.The aim of the study was to conduct a historical analysis and comprehensive review of the current state of legal and regulatory framework of the Russian pharmaceutical market in the field of compounding drugs, as well as to develop proposals for improving the regulatory field.Materials and methods. The following methodological tools – empirical, theoretical, quantitative ones – have been used in the work. In particular, an analysis of a wide range of relevant sources of information was carried out and information was obtained from legal and regulatory framework for the activities of compounding pharmacies in the Russian Federation, which was implemented using a bibliometric method of analysis.Results. The main elements of the Russian legislation in the field of drug circulation with the aim of a comprehensive understanding of the classification and determination of the role of extemporaneous drugs in the Russian healthcare system, are presented in the article. A historical and technical analysis of the regulatory practice development is consistently presented. The key issues of organizing the pharmaceutical business in the field of compounding and dispensing of drugs on the territory of the Russian Federation have been considered, and current problems that need to be solved when improving the regulatory field, are presented.Conclusion. The review conducted makes it possible to clarify further actions to improve federal legislation and delegated legislation in the field of circulation of compounded drugs by pharmacy organizations. The work presents recommendations that will contribute to the development of compounding pharmacies in the constituent entities of the Russian Federation.


  • Open Access

    New role of extemporaneous manufacturing in regulating drug products access onto the market

    by A. V. Alekhin, T. N. Erivantseva, V. V. Ryazhenov, N. N. Lyskov, N. A. Alekhina, M. M. Kuznetsova

    The aim of the work was to study the legal aspects of the legislative regulation for manufacturing medicines in a pharmacy organization.Materials and methods. Databases of ConsultantPlus, Cyberleninka, Food and Drug Administration (FDA), European Medicines Agency (EMA), National Center for Biotechnology Information (NCBI), PubMed, e-library, WIPO Lex were used as search sources. The search was based on the following keywords and phrases: intellectual property, pharmacies+invention, patent, drugs, extemporal+production, orphan+diseases, as well as their Russian counterparts. 133 sources of information, including scientific articles and regulations, were found out; 50 have been included in this review. The analysis of information sources published from 2013 to 2023, was determined by the peculiarities of legislation changes in this area.Results. The article provided an overview of modern, including regulatory practice, pharmaceutical manufacturing in the Russian Federation, and also analyzed the benefits of this activity for the medical community, patients and the state. At the same time, the individualization of drug treatment has made it possible to work out systemic solutions for developing drug therapy methods for special groups of patients for whom the economic feasibility of a pharmaceutical registration and launching such drugs onto the market has been brought into challenge. In addition, pharmacy manufacturing is an accessible tool in the study of the drugs prescribed by a doctor not in accordance with the instructions for medical use (off-label) or in the dosage forms/dosages that are not on the market. Extemporaneous manufacturing can be also a part of the process of “repositioning” drugs on the market, subject to compliance with the requirements for pharmacy manufacturing and control of the prescribed drugs safety. The possibility of pharmaceutic drug manufacturing also makes it possible to partially resolve issues related to intellectual property. As a result of the carried out analysis, the following hypothesis was confirmed: the legislative changes have a similar legal assessment both in Russia and abroad and correspond to the legal practice in resolving intellectual property issues in relation to pharmacy organizations.Conclusion. The renewal of a pharmacy production will improve the availability of the drug care to the population, taking into account individual dosages and dosage forms in various therapeutic areas, and can also become a tool for repositioning drugs or clinical testing of new molecules for rare incurable diseases.